54,441 Shares in DaVita Inc. (NYSE:DVA) Purchased by Quantbot Technologies LP

Quantbot Technologies LP bought a new stake in DaVita Inc. (NYSE:DVA) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 54,441 shares of the company’s stock, valued at approximately $8,925,000. Quantbot Technologies LP owned about 0.07% of DaVita as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in DVA. FMR LLC boosted its holdings in DaVita by 659.9% in the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock valued at $29,082,000 after purchasing an additional 154,061 shares during the period. Bank of Montreal Can raised its position in shares of DaVita by 0.9% during the third quarter. Bank of Montreal Can now owns 60,929 shares of the company’s stock valued at $9,936,000 after buying an additional 520 shares during the last quarter. Harvest Fund Management Co. Ltd lifted its stake in shares of DaVita by 14.4% in the third quarter. Harvest Fund Management Co. Ltd now owns 11,142 shares of the company’s stock valued at $1,826,000 after buying an additional 1,399 shares during the period. Daiwa Securities Group Inc. grew its position in DaVita by 6.0% during the third quarter. Daiwa Securities Group Inc. now owns 6,187 shares of the company’s stock worth $1,014,000 after buying an additional 348 shares in the last quarter. Finally, Summit Trail Advisors LLC increased its stake in DaVita by 1.3% during the third quarter. Summit Trail Advisors LLC now owns 23,309 shares of the company’s stock valued at $3,821,000 after acquiring an additional 294 shares during the period. 90.12% of the stock is owned by institutional investors.

DaVita Stock Performance

Shares of NYSE:DVA opened at $166.99 on Tuesday. The stock has a market capitalization of $13.69 billion, a price-to-earnings ratio of 18.01, a price-to-earnings-growth ratio of 0.93 and a beta of 0.89. The business’s fifty day moving average price is $158.34 and its two-hundred day moving average price is $148.65. DaVita Inc. has a fifty-two week low of $98.26 and a fifty-two week high of $169.12. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The firm had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter last year, the business earned $2.85 EPS. As a group, analysts predict that DaVita Inc. will post 9.71 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on DVA shares. UBS Group raised their price objective on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Bank of America lifted their price target on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. Barclays increased their price objective on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Finally, Truist Financial lifted their target price on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, DaVita presently has a consensus rating of “Hold” and an average target price of $161.80.

Insider Activity at DaVita

In other DaVita news, CEO Javier Rodriguez sold 50,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the sale, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. This trade represents a 5.63 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 2.00% of the company’s stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.